doi: 10.1016/0022-4731(90)90013-i.
Toremifene, a new antiestrogenic compound in the treatment of metastatic mammary cancer. A phase II study
Affiliations
- PMID: 2142241
- DOI: 10.1016/0022-4731(90)90013-i
Item in Clipboard
Toremifene, a new antiestrogenic compound in the treatment of metastatic mammary cancer. A phase II study
J Steroid Biochem.
.
Abstract
Toremifene is a new antiestrogenic compound. Toremifene has definite antitumor effect in advanced breast cancer. The response rate in the present phase II study among postmenopausal women, mostly not pretreated with systemic therapy and with ER positive or not determined ER status in tumor tissue, was 11/23 (48%; 95% confidence interval 37-59%) including 6 complete responses. The toxicity profile was similar to that of tamoxifen. It is concluded that toremifene is at least as active as tamoxifen in advanced breast cancer and that a randomized study between these two antiestrogens is indicated.
Similar articles
-
Phase II clinical study of toremifene in patients with metastatic breast cancer. Preliminary communication.J Steroid Biochem. 1990 Jun 22;36(3):235-6. doi: 10.1016/0022-4731(90)90014-j. J Steroid Biochem. 1990. PMID: 2142242
-
Treatment of advanced breast cancer with 20 mg toremifene, a phase II study. Preliminary communication.J Steroid Biochem. 1990 Jun 22;36(3):227-8. doi: 10.1016/0022-4731(90)90011-g. J Steroid Biochem. 1990. PMID: 2142239
-
[The results of a comparative clinical study of the antiestrogenic preparations toremifene and tamoxifen in locally advanced and disseminated breast cancer].Vopr Onkol. 1990;36(10):1182-6. Vopr Onkol. 1990. PMID: 2147527 Clinical Trial. Russian.
-
Phase II trials with toremifene in advanced breast cancer: a review.Breast Cancer Res Treat. 1990 Aug;16 Suppl:S31-5. doi: 10.1007/BF01807142. Breast Cancer Res Treat. 1990. PMID: 2149283 Review.
-
Introduction to toremifene.Breast Cancer Res Treat. 1990 Aug;16 Suppl:S3-7. doi: 10.1007/BF01807138. Breast Cancer Res Treat. 1990. PMID: 2149282 Review.
Cited by
-
High dose toremifene for estrogen and progesterone receptor negative metastatic breast cancer: a phase II trial of the Cancer and Leukemia Group B (CALGB).Breast Cancer Res Treat. 1995;36(1):35-40. doi: 10.1007/BF00690182. Breast Cancer Res Treat. 1995. PMID: 7579504 Clinical Trial.
-
Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer.Drugs. 1997 Jul;54(1):141-60. doi: 10.2165/00003495-199754010-00014. Drugs. 1997. PMID: 9211086 Review.
-
Toremifene and tamoxifen in advanced breast cancer--a double-blind cross-over trial.Breast Cancer Res Treat. 1993;25(1):57-63. doi: 10.1007/BF00662401. Breast Cancer Res Treat. 1993. PMID: 8518408 Clinical Trial.
-
Comparative tolerability of first-generation selective estrogen receptor modulators in breast cancer treatment and prevention.Drug Saf. 2001;24(14):1039-53. doi: 10.2165/00002018-200124140-00003. Drug Saf. 2001. PMID: 11735660 Review.
-
Atypical McMurry cross-coupling reactions leading to a new series of potent antiproliferative compounds bearing the key [ferrocenyl-ene-phenol] motif.Molecules. 2014 Jul 17;19(7):10350-69. doi: 10.3390/molecules190710350. Molecules. 2014. PMID: 25036149 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Medical